Coherus Oncology: The Catalyst Rich Period Is Here

Impact · against what's priced in

Coherus Oncology faces a high-volatility period with several critical clinical readouts scheduled for H2'26 and H1'27. While Loqtorzi revenue growth provides a baseline, the potential for dilutive capital raises remains a primary risk to valuation.

CHRS+0.40

No priced-in read yet

In context

The upcoming readouts for tagmokitug and casdozokitug in H2'26 and H1'27 create significant binary catalysts, while projected growth in Loqtorzi revenues offsets some risk of future capital raises.

Read from the article alone

• biotech
• CHRS
• capital raise
• clinical trials
• drug pipeline
• oncology
• revenue guidance

Search tags